Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00962689 · ClinicalTrials.gov registry record

Clinical Study to Improve Diagnosis and Treatment of Sinusitis

A clinical trial, sponsored by Ohio State University.

Completed
Registry status
38
Enrollment target

NCT00962689: Completed study, sponsored by Ohio State University.

NCT00962689 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00962689 has completed, sponsored by Ohio State University.

COMPLETED
Registry status
38 participants
Enrollment target

Study Summary

Chronic rhinosinusitis (CRS) is the most common chronic medical condition that affects Americans between 18-44 years of age. While significant advances have been made in the understanding of the molecular pathogenesis underlying many subtypes of CRS, this has not translated into widespread changes in how physicians manage adult or pediatric CRS. The focus of this study is intended to develop testing methods to improve the objectivity and specificity of diagnosis and allow for individualized therapy with less invasive, customized treatments instead of the traditional, empiric based, and radically exenterative therapies commonly employed in clinical practice. Specifically, it is now known that many patients with CRS have a greater concentration of non-typeable Haemophilus influenzae (NTHI) in the bacterial biofilms located within their sinus cavities compared to healthy patients. The specific hypothesis behind the proposed research is that the presence of NTHI biofilms, which are known to be highly recalcitrant, are positively correlated with the development of CRS and that unique lipooligosaccharides and inflammatory byproducts obtained from nasopharyngeal lavage fluids and/or swabs of sinus secretions may be used as a non-invasive biomarker for CRS. As a result, patients with symptoms of CRS specifically associated with NTHI biofilms could possibly obtain a non-invasive test in the physician's office that would allow the clinician to make a more accurate diagnosis and objectively follow each patient's responsiveness to customized therapy.

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2009-08
Est. Completion 2013-11
Ohio State University

552 total trials

What the finished NCT00962689 record still lists

NCT00962689 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00962689 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00962689 about?

NCT00962689 is a clinical study titled "Clinical Study to Improve Diagnosis and Treatment of Sinusitis". Chronic rhinosinusitis (CRS) is the most common chronic medical condition that affects Americans between 18-44 years of age. While significant advances have been made in the understanding of the molecular pathogenesis underlying many subtypes of CRS, this has not translated into widespread changes i...

What is the current status of trial NCT00962689?

This trial is currently completed. The enrollment target is 38 participants. The study started on 2009-08. Estimated completion is 2013-11.

Who is sponsoring clinical trial NCT00962689?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00962689, the US trial registry maintained by the National Library of Medicine. NCT00962689 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.